Terms: = Prostate cancer AND CDKN2C, P42773, 1031, ENSG00000123080, INK4C, p18, p18-INK4C
73 results:
1. [
Oprea-Lager DE; Gontier E; García-Cañamaque L; Gauthé M; Olivier P; Mitjavila M; Tamayo P; Robin P; García Vicente AM; Bouyeure AC; Bailliez A; Rodríguez-Fernández A; Mahmoud SB; Vallejo-Casas JA; Maksud P; Merlin C; Blanc-Durand P; Drouet C; Tissot H; Vierasu I; Vander Borght T; Boos E; Chossat F; Hodolic M; Rousseau C
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3439-3451. PubMed ID: 37341747
[TBL] [Abstract] [Full Text] [Related]
2. Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men.
Siddiqui MR; Li EV; Kumar SKSR; Busza A; Lin JS; Mahenthiran AK; Aguiar JA; Shah PV; Ansbro B; Rich JM; Moataz SAS; Keeter MK; Mai Q; Mi X; Tosoian JJ; Schaeffer EM; Patel HD; Ross AE
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):588-595. PubMed ID: 36973367
[TBL] [Abstract] [Full Text] [Related]
3. Regional differences in total hospital costs for radical cystectomy in the United States.
Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Antonelli A; Kluth LA; Becker A; Chun FKH; Karakiewicz PI
Surg Oncol; 2023 Jun; 48():101924. PubMed ID: 36948042
[TBL] [Abstract] [Full Text] [Related]
4. Design, Synthesis, and Anti-cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine.
Zhang L; Qi K; Xu J; Xing Y; Wang X; Tong L; He Z; Xu W; Li X; Jiang Y
J Med Chem; 2023 Mar; 66(6):4150-4166. PubMed ID: 36867101
[TBL] [Abstract] [Full Text] [Related]
5. Using health insurance claims data to assess long-term disease progression in a prostate cancer cohort.
Khan S; Vohra S; Farnan L; Elmore SNC; Toumbou K; K C M; Fontham ETH; Peters ES; Mohler JL; Bensen JT
Prostate; 2022 Nov; 82(15):1447-1455. PubMed ID: 35880605
[TBL] [Abstract] [Full Text] [Related]
6. Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic prostate cancer.
Wallis CJD; Malone S; Cagiannos I; Morgan SC; Hamilton RJ; Basappa NS; Ferrario C; Gotto GT; Fernandes R; Niazi T; Noonan KL; Saad F; Hotte SJ; Hew H; Chan KFY; Wyllie LP; Shayegan B
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34926988
[TBL] [Abstract] [Full Text] [Related]
7. AFP peptide (AFPep) as a potential growth factor for prostate cancer.
Zhu Z; West GR; Wang DC; Collins AB; Xiao H; Bai Q; Mesfin FB; Wakefield MR; Fang Y
Med Oncol; 2021 Nov; 39(1):2. PubMed ID: 34739644
[TBL] [Abstract] [Full Text] [Related]
8. Progression-free survival in patients with
Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM
Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648
[TBL] [Abstract] [Full Text] [Related]
9. Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target cancer Stem Cells
Slusarczyk M; Serpi M; Ghazaly E; Kariuki BM; McGuigan C; Pepper C
J Med Chem; 2021 Jun; 64(12):8179-8193. PubMed ID: 34085825
[TBL] [Abstract] [Full Text] [Related]
10. Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens.
Rijstenberg LL; Hansum T; Hollemans E; Kweldam CF; Kümmerlin IP; Bangma CH; van der Kwast TH; Roobol MJ; van Leenders GJLH
Histopathology; 2020 Nov; 77(5):742-748. PubMed ID: 32542746
[TBL] [Abstract] [Full Text] [Related]
11. Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic prostate cancer: Evaluation of Clinical Biomarker Potential.
Bjerre MT; Nørgaard M; Larsen OH; Jensen SØ; Strand SH; Østergren P; Fode M; Fredsøe J; Ulhøi BP; Mortensen MM; Jensen JB; Borre M; Sørensen KD
Cells; 2020 May; 9(6):. PubMed ID: 32486483
[TBL] [Abstract] [Full Text] [Related]
12. Improved prostate cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
van Leenders GJLH; Kweldam CF; Hollemans E; Kümmerlin IP; Nieboer D; Verhoef EI; Remmers S; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ
Eur Urol; 2020 Feb; 77(2):191-198. PubMed ID: 31439369
[TBL] [Abstract] [Full Text] [Related]
13. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced prostate cancer by Pre-existing Cardiovascular Comorbidities.
Lu-Yao G; Nikita N; Keith SW; Nightingale G; Gandhi K; Hegarty SE; Rebbeck TR; Chapman A; Kantoff PW; Cullen J; Gomella L; Kelly WK
Eur Urol; 2020 Feb; 77(2):158-166. PubMed ID: 31420248
[TBL] [Abstract] [Full Text] [Related]
14. Prevalence and predictors of probable depression in prostate cancer survivors.
Erim DO; Bensen JT; Mohler JL; Fontham ETH; Song L; Farnan L; Delacroix SE; Peters ES; Erim TN; Chen RC; Gaynes BN
Cancer; 2019 Oct; 125(19):3418-3427. PubMed ID: 31246284
[TBL] [Abstract] [Full Text] [Related]
15. Dietary inflammatory index and cancer risk in the elderly: A pooled-analysis of Italian case-control studies.
Accardi G; Shivappa N; Di Maso M; Hébert JR; Fratino L; Montella M; La Vecchia C; Caruso C; Serraino D; Libra M; Polesel J
Nutrition; 2019; 63-64():205-210. PubMed ID: 31029049
[TBL] [Abstract] [Full Text] [Related]
16. Prospective, Multisite, International Comparison of
Emmett L; Metser U; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Punwani S; Pond G; Chua S; Ho B; Johnston E; Pouliot F; Scott AM
J Nucl Med; 2019 Jun; 60(6):794-800. PubMed ID: 30442757
[TBL] [Abstract] [Full Text] [Related]
17. Complementary Medicine, Refusal of Conventional cancer Therapy, and Survival Among Patients With Curable cancers.
Johnson SB; Park HS; Gross CP; Yu JB
JAMA Oncol; 2018 Oct; 4(10):1375-1381. PubMed ID: 30027204
[TBL] [Abstract] [Full Text] [Related]
18. Adjustable transobturator male system (ATOMS
Angulo JC; Fonseca J; Esquinas C; Ojea A; Rodríguez A; Rabassa M; Teba F; Escribano G; Cruz F
Actas Urol Esp (Engl Ed); 2018 Nov; 42(9):567-573. PubMed ID: 29929737
[TBL] [Abstract] [Full Text] [Related]
19. Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7.
Verhoef EI; Kweldam CF; Kümmerlin IP; Nieboer D; Bangma CH; Incrocci L; van der Kwast TH; Roobol MJ; van Leenders GJ
Histopathology; 2018 Apr; 72(5):760-765. PubMed ID: 29094386
[TBL] [Abstract] [Full Text] [Related]
20. Comparative Analysis of Clinical Outcomes and Procedural Costs between the Conventional Two-stage Technique and 4D Brachytherapy for Early prostate cancer.
Langley SEM; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Khaksar S; Soares R; Laing R
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):57-64. PubMed ID: 29054374
[TBL] [Abstract] [Full Text] [Related]
[Next]
